logo-loader
viewSynairgen PLC

Synairgen to share encouraging data

The company’s chief scientific officer, Dr Phillip Monk, will deliver the update on Sunday (Sept 29) to the European Respiratory Society International Congress being held in Madrid

Synairgen PLC -
Synairgen is a respiratory drug discovery and development company

Synairgen PLC (LON:SNG) said it is presenting data at an industry conference gleaned from a phase II study of its inhaled interferon beta treatment for patients with chronic obstructive pulmonary disease (COPD).

The drug is being developed to treat people with COPD that are suffering exacerbations caused by cold or flu.

The biomarker data has been taken from part-one of the study, in which patients were treated when they did not have a cold or flu infection.

Analysis of samples from the lung showed treatment with inhaled interferon beta boosted the lungs' antiviral defences.

As a result, Synairgen is now more confident of a positive result from part-two, when patients do have a confirmed respiratory virus infection.

The company’s chief scientific officer, Dr Phillip Monk, will deliver the update on Sunday (Sept 29) to the European Respiratory Society International Congress being held in Madrid.

Quick facts: Synairgen PLC

Price: 7.625 GBX

AIM:SNG
Market: AIM
Market Cap: £8.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

on 30/9/19

2 min read